What is the current Antibodies in Oncology market size?

The current Antibodies in Oncology market size is approximately USD 42.8 billion as of 2022.

What is the expected growth forecast for the market?

The Antibodies in Oncology market is expected to grow at a CAGR of 10.3% from 2023 to 2028.

What are the key drivers of the Antibodies in Oncology market?

Key drivers include increasing cancer prevalence and rising demand for targeted therapies.

What are the major challenges faced by the Antibodies in Oncology market?

Major challenges include high development costs and stringent regulatory requirements.

Which regions are leading the Antibodies in Oncology market?

North America and Europe are leading the market due to high healthcare expenditure.

Who are the top companies in the Antibodies in Oncology market?

Top companies include Roche, Merck, and Pfizer, which offer a range of oncology treatments.

What are the future opportunities in the Antibodies in Oncology market?

Future opportunities include emerging markets and increasing use of combination therapies.

How is technology impacting the Antibodies in Oncology market?

Technology is advancing drug development and improving treatment outcomes through precision medicine.

What is the current regulatory landscape for the Antibodies in Oncology market?

The regulatory landscape is evolving with ongoing updates to guidelines and approvals for new treatments.

What is the future outlook for the Antibodies in Oncology market?

The future outlook is positive with increasing investment in research and development of new therapies.

Antibodies in Oncology Trends, Opportunities & Forecast 2033

Antibodies in Oncology by Type (/> Murine Antibodies, Chimeric and Humanised Antibodies, Fully Humanized Antibodies, Others), by Application (/> Hospitals, Academic Institutes, Clinics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Antibodies in Oncology Market Size | CAGR 10.2 Forecast 2033

Antibodies in Oncology Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Antibodies in Oncology Market Overview

The Antibodies in Oncology market refers to the industry involved in the development and application of antibodies for cancer treatment. As a crucial segment of the broader oncology market, the Antibodies in Oncology market size is estimated to be approximately $44.6 billion in 2025. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of around 10.3% during the forecast period of 2026-2033. This industry expansion is driven by increasing demand for targeted and immunotherapeutic cancer treatments, advancements in technology, and rising investments in research and development. The scope of this market encompasses various types of antibodies, including monoclonal antibodies, and their applications across different cancer types.

Loading chart…

Key forces shaping the Antibodies in Oncology industry include technology shifts towards more personalized and targeted therapies, regulatory environments that encourage innovation while ensuring safety and efficacy, and consumer behavior that increasingly demands more effective and less invasive treatments. The largest region for this market is currently North America, driven by high healthcare expenditure and a strong presence of pharmaceutical and biotechnology companies. The fastest-growing region is expected to be Asia-Pacific, driven by increasing investment in healthcare infrastructure and research capabilities. Overall, the Antibodies in Oncology market is poised for significant growth, driven by these macro drivers and the ongoing quest for more effective cancer treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis International AG; GlaxoSmithKline plc; Biogen Idec Inc.; Bristol Myers Squibb Co.; AstraZeneca plc.; Celltrion; 3SBIO; Celgen Biopharma; Dr Reddy’s
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Antibodies in Oncology market is poised for significant growth, driven by increasing demand for targeted therapies and advancements in cancer research. The global Antibodies in Oncology market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Rising prevalence of cancer and the need for effective treatments are driving the adoption of Antibodies in Oncology, leading to increased market size and growth

Advances in antibody engineering and technologies, such as bispecific antibodies, are enhancing the efficacy and safety of cancer treatments, further fueling the growth forecast of the Antibodies in Oncology market

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the Antibodies in Oncology market, making it challenging for new entrants to compete with established players

The complex and time-consuming process of antibody development, from discovery to commercialization, is a significant restraint on the Antibodies in Oncology market size and its overall growth potential

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies presents opportunities for the development of innovative Antibodies in Oncology, driving market growth and expansion

Emerging markets and the growing demand for cancer treatments in developing countries offer significant opportunities for the Antibodies in Oncology market to increase its global footprint and growth forecast

Challenges2 items

The Antibodies in Oncology market faces challenges from the increasing competition and patent expirations of existing therapies, which may impact the market size and growth forecast

Ensuring access to affordable cancer treatments, particularly in low- and middle-income countries, is a significant challenge that the Antibodies in Oncology market must address to achieve sustainable growth and development

Market Segmentation

Loading chart…

The Type segment in the Antibodies in Oncology market refers to the different classes of antibodies used in cancer treatment. This segmentation category contributes to the overall market size by highlighting the various types of antibodies, such as monoclonal antibodies, polyclonal antibodies, and bispecific antibodies, each with its own unique characteristics and applications. Understanding the type of antibodies used is crucial in Antibodies in Oncology segmentation as it helps in identifying the most effective treatment options for specific cancer types.

The Application segment in the Antibodies in Oncology market is further divided into subtypes, including breast cancer, lung cancer, colorectal cancer, and others. This segmentation category plays a significant role in determining the overall market size as it outlines the various cancer types that antibodies are used to treat. By analyzing the application segment, researchers can identify the most prevalent cancer types and develop targeted antibody-based treatments, ultimately contributing to the growth of the market taxonomy in the Antibodies in Oncology industry.

Antibodies in Oncology Segmentation Breakdown9 items

Type

/> Murine Antibodies

Chimeric and Humanised Antibodies

Fully Humanized Antibodies

Others

Application

/> Hospitals

Academic Institutes

Clinics

Regional Insights

Loading chart…

The Antibodies in Oncology market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of innovative cancer treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and growing adoption of immunotherapies. Asia Pacific's growth is driven by large demographics, increasing adoption of innovative treatments, and significant investments in healthcare. Latin America's growth is driven by growing adoption and increasing investments, while Middle East & Africa's growth is driven by improving infrastructure and increasing adoption.

The regional forecast indicates that the Asia Pacific region will experience the highest Antibodies in Oncology market growth, driven by its large and growing population, increasing adoption of innovative cancer treatments, and significant investments in healthcare infrastructure. As the market continues to evolve, understanding the key drivers and trends in each region will be crucial for stakeholders to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Antibodies in Oncology market exhibits a moderately consolidated structure, with a mix of global players and local companies competing for market share. The Antibodies in Oncology competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional expansion and partnerships to stay competitive.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

Novartis International AG: regional expansion

GlaxoSmithKline plc: innovation pipeline

Biogen Idec Inc.: premium pricing

Bristol Myers Squibb Co.: OEM tie-ups

AstraZeneca plc.: local manufacturing

Celltrion: vertical integration

Key Antibodies in Oncology Companies9 items

Novartis International AG

GlaxoSmithKline plc

Biogen Idec Inc.

Bristol Myers Squibb Co.

AstraZeneca plc.

Celltrion

3SBIO

Celgen Biopharma

Dr Reddy’s

Market Ecosystem

The Antibodies in Oncology ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main categories: upstream, midstream, and downstream. Upstream participants, such as technology providers and raw material suppliers, create and supply essential components. Midstream players, including manufacturers and system integrators, integrate these components into final products. Downstream channels, comprising distributors and service providers, deliver these products to end users, where value is ultimately captured.

Raw material suppliers — provide essential antibodies and components

Technology providers — develop and license relevant technologies

OEMs/manufacturers — produce and package final antibody products

System integrators/EPCs — integrate antibodies into therapeutic solutions

Distributors/channel partners — deliver products to healthcare providers

Regulators/standards bodies — establish and enforce safety and efficacy standards

End users/buyers — administer antibodies to patients and provide feedback

In the Antibodies in Oncology ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as limited supply of raw materials, and standards compliance. Switching costs are significant due to the high specificity of antibody products, leading to strong partnerships between suppliers and manufacturers. As part of a thorough value chain analysis, understanding these dynamics is crucial to navigating the ecosystem. The ecosystem's structure and dependencies can vary by region, with different regulatory frameworks and market conditions affecting the flow of value.

Recent Industry Insights

The Antibodies in Oncology industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in the field. Notable mergers and acquisitions have also taken place, with companies seeking to expand their portfolios and strengthen their positions in the market. Furthermore, several product and technology launches have been announced, offering new treatment options for patients with various types of cancer.

Regulatory changes have also impacted the industry, with updates to guidelines and approvals for new therapies. Additionally, there has been a shift in consumer and enterprise trends, with a growing focus on personalized medicine and immunotherapy. Funding rounds and expansions have supported the growth of companies in the sector, enabling them to invest in research and development and bring new treatments to market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Antibodies in Oncology market outlook. The market attractiveness is high, driven by increasing demand for targeted therapies and a strong pipeline of innovative treatments. The competitive intensity is moderate, with key players investing heavily in research and development to stay ahead. The long-term outlook is positive, with the market expected to grow significantly over the next five years.

The innovation landscape is rapidly evolving, with advancements in immunotherapy and combination therapies offering new opportunities for growth. However, the demand–supply balance is a key concern, with manufacturing capacity and regulatory frameworks posing challenges. Key risk factors include regulatory changes and patent expirations, which could impact market dynamics. Overall, the Antibodies in Oncology market presents a compelling opportunity for investors and manufacturers, with a strong potential for growth and innovation.

11 items

1. Executive Summary

2. Antibodies in Oncology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antibodies in Oncology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Antibodies in Oncology Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Murine Antibodies

6.1.2. Chimeric and Humanised Antibodies

6.1.3. Fully Humanized Antibodies

6.1.4. Others

6.2. Global Antibodies in Oncology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Academic Institutes

6.2.3. Clinics

6.3. Global Antibodies in Oncology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Antibodies in Oncology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antibodies in Oncology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Antibodies in Oncology Market Competition by Key Manufacturers

8.1. Global Antibodies in Oncology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Antibodies in Oncology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis International AG

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GlaxoSmithKline plc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Biogen Idec Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bristol Myers Squibb Co.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca plc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Celltrion

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. 3SBIO

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Celgen Biopharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Dr Reddy’s

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antibodies in Oncology Market

Figure 4: Global Antibodies in Oncology Market: Drivers

Figure 5: Global Antibodies in Oncology Market: Challenges

Figure 6: Global Antibodies in Oncology Market: Trends

Figure 7: Global Antibodies in Oncology Market: Opportunity

Figure 8: Global Antibodies in Oncology Market: Restraint

Figure 9: Global Antibodies in Oncology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Antibodies in Oncology Market Value (USD Million) By Region

Figure 15: Global Antibodies in Oncology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Antibodies in Oncology Market Value (USD Million) By Region

Figure 23: Global Antibodies in Oncology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Antibodies in Oncology Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Antibodies in Oncology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Antibodies in Oncology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Antibodies in Oncology Market Value (USD Million) By Region

Table 10: Global Antibodies in Oncology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Antibodies in Oncology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Antibodies in Oncology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Antibodies in Oncology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis International AG Basic Information And Sales Area

Table 31: Novartis International AG. Products Portfolio

Table 32: GlaxoSmithKline plc Basic Information And Sales Area

Table 33: GlaxoSmithKline plc. Products Portfolio

Table 34: Biogen Idec Inc. Basic Information And Sales Area

Table 35: Biogen Idec Inc.. Products Portfolio

Table 36: Bristol Myers Squibb Co. Basic Information And Sales Area

Table 37: Bristol Myers Squibb Co.. Products Portfolio

Table 38: AstraZeneca plc. Basic Information And Sales Area

Table 39: AstraZeneca plc.. Products Portfolio

Table 40: Celltrion Basic Information And Sales Area

Table 41: Celltrion. Products Portfolio

Table 42: 3SBIO Basic Information And Sales Area

Table 43: 3SBIO. Products Portfolio

Table 44: Celgen Biopharma Basic Information And Sales Area

Table 45: Celgen Biopharma. Products Portfolio

Table 46: Dr Reddy’s Basic Information And Sales Area

Table 47: Dr Reddy’s. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Antibodies in Oncology Market Value (USD Million) By Region

Table 53: Global Antibodies in Oncology Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Antibodies in Oncology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis International AG; GlaxoSmithKline plc; Biogen Idec Inc.; Bristol Myers Squibb Co.; AstraZeneca plc.; Celltrion; 3SBIO; Celgen Biopharma; Dr Reddy’s
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options